Zacks Research Comments on ResMed Inc.’s Q1 2025 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Research analysts at Zacks Research upped their Q1 2025 earnings per share estimates for ResMed in a research note issued on Monday, April 8th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $1.94 per share for the quarter, up from their prior estimate of $1.93. The consensus estimate for ResMed’s current full-year earnings is $7.45 per share. Zacks Research also issued estimates for ResMed’s FY2025 earnings at $8.04 EPS and FY2026 earnings at $8.65 EPS.

Other research analysts also recently issued reports about the company. Oppenheimer upped their price target on ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Needham & Company LLC upped their price target on ResMed from $215.00 to $224.00 and gave the company a “buy” rating in a report on Monday, April 1st. KeyCorp initiated coverage on ResMed in a report on Tuesday, February 6th. They issued an “overweight” rating and a $227.00 target price on the stock. UBS Group increased their target price on ResMed from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Finally, Mizuho reissued a “buy” rating and issued a $215.00 target price on shares of ResMed in a report on Wednesday, March 27th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $199.20.

ResMed Trading Down 0.2 %

NYSE RMD opened at $193.83 on Thursday. The stock has a market cap of $28.51 billion, a P/E ratio of 32.04, a P/E/G ratio of 2.32 and a beta of 0.67. The company has a current ratio of 3.11, a quick ratio of 1.89 and a debt-to-equity ratio of 0.27. ResMed has a 12 month low of $132.24 and a 12 month high of $243.52. The stock’s fifty day moving average price is $187.09 and its 200-day moving average price is $168.83.

ResMed (NYSE:RMD) last released its earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the prior year, the firm posted $1.66 earnings per share. The company’s quarterly revenue was up 12.5% on a year-over-year basis.

Institutional Trading of ResMed

Several institutional investors have recently made changes to their positions in RMD. Norges Bank purchased a new stake in shares of ResMed during the fourth quarter worth about $233,966,000. Morgan Stanley grew its holdings in ResMed by 102.4% during the 3rd quarter. Morgan Stanley now owns 2,329,618 shares of the medical equipment provider’s stock valued at $344,481,000 after buying an additional 1,178,547 shares in the last quarter. LGT Capital Partners LTD. purchased a new position in ResMed during the 4th quarter valued at approximately $117,621,000. FIL Ltd grew its holdings in ResMed by 245.9% during the 4th quarter. FIL Ltd now owns 840,030 shares of the medical equipment provider’s stock valued at $144,502,000 after buying an additional 597,165 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in ResMed by 3,599.0% during the 1st quarter. Los Angeles Capital Management LLC now owns 499,031 shares of the medical equipment provider’s stock valued at $98,823,000 after buying an additional 485,540 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Transactions at ResMed

In other news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the transaction, the general counsel now owns 6,688 shares of the company’s stock, valued at $1,158,696. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Peter C. Farrell sold 10,935 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the completion of the sale, the director now owns 157,404 shares in the company, valued at $28,751,414.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Michael J. Rider sold 200 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the sale, the general counsel now owns 6,688 shares of the company’s stock, valued at approximately $1,158,696. The disclosure for this sale can be found here. Insiders have sold 11,216 shares of company stock valued at $2,046,617 over the last quarter. 1.21% of the stock is currently owned by company insiders.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Thursday, February 8th were paid a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 0.99%. The ex-dividend date was Wednesday, February 7th. ResMed’s dividend payout ratio (DPR) is currently 31.74%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.